XKRX
000520
Market cap86mUSD
Jul 10, Last price
6,280.00KRW
1D
2.95%
1Q
-34.45%
Jan 2017
70.00%
Name
Samil Pharmaceutical Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Samil Pharmaceutical Co.,Ltd, a South Korean entity, is primarily engaged in manufacturing and distributing vital medical products. Its comprehensive pharmaceutical range addresses a wide array of health conditions, encompassing treatments for hepatic, gastrointestinal, cardiovascular (vasodilator, antithrombotic, circulatory), respiratory, musculoskeletal (skeletal muscle relaxants), neurological, and infectious diseases (antibiotics). The portfolio further extends to metabolic, allergic (antihistamines), immunological (immunosuppressive), endocrine (hormone), oncological (anti-tumor), urological, and ophthalmic disorders, alongside medications for fever, pain, and inflammation. Beyond prescription drugs, Samil Pharmaceutical also offers a selection of over-the-counter (OTC) products and personal hygiene supplies. Established in Seoul, South Korea, in 1947, the company maintains its headquarters there.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||